Posted: 27 November 2024
Medicines Australia welcomes the announcement of the independent HTA Reform Implementation Advisory Group and the appointment of CEO Liz de Somer and Board Deputy Chair Anne Harris as industry’s representatives.
“The independent Implementation Advisory Group announced today by Minister Butler is a step forward in progressing HTA reform, and will enable Australia to get on with fixing our broken system so patients can access new medicines without unnecessary delay,” Medicines Australia CEO Liz de Somer said.
“As Chair, Prof Andrew Wilson AO will bring unparalleled experience and understanding of the challenges in our current HTA system, and his collaborative, solution-focused approach will be needed as we move through the complexities.”
“I’m pleased to join Prof Wilson in providing consistency from the HTA Review reference committee, which will be crucial to guiding the intent of the review’s recommendations is carried through reform implementation.”
“The appointment of a second industry representative, Medicines Australia Deputy Chair Anne Harris, is greatly welcomed and recognises the significant time investment required to deliver this important package of reforms.”
“Anne is highly regarded across the industry, and will bring unique insight and extensive experience to the discussions.”
“We also welcome the inclusion of the enhanced consumer engagement framework in the remit of the Implementation Advisory Group, and strong consumer representation in the group.”
“With an election looming, it is important that we now get to work in developing an implementation plan and timelines, and commence the co-design work that is needed to deliver these reforms.”
